Frankfurt - Delayed Quote EUR

HBM Holdings Limited (6XY.F)

Compare
0.4700
-0.0350
(-6.93%)
At close: 3:29:01 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 6XY.F

Recent News: 6XY.F

View More
February 2025 Undervalued Small Caps With Insider Action Across Regions

February 2025 Undervalued Small Caps With Insider Action Across Regions
Simply Wall St. 8 days ago
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
PR Newswire 8 days ago
Quanzhou Huixin Micro-credit And 2 Other Promising Penny Stocks To Watch

Quanzhou Huixin Micro-credit And 2 Other Promising Penny Stocks To Watch
Simply Wall St. 27 days ago

Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD
GlobeNewswire last month
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
PR Newswire last month
HBM Holdings And 2 Other Promising Penny Stocks

HBM Holdings And 2 Other Promising Penny Stocks
Simply Wall St. last month
3 Promising Penny Stocks With Market Caps Over US$70M

3 Promising Penny Stocks With Market Caps Over US$70M
Simply Wall St. 2 months ago
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
PR Newswire 2 months ago
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
PR Newswire 3 months ago
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
PR Newswire 4 months ago
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
PR Newswire 4 months ago
View More

Related Tickers

6K9.F Context Therapeutics Inc.
0.7300
+2.10%
 
CRO.F hVIVO plc
0.1900
-0.52%
 
PHPN.F Galectin Therapeutics Inc.
1.2000
-2.44%
 
1U5.F Wave Life Sciences Ltd.
10.20
+4.62%
 
EU6.F PDS Biotechnology Corporation
1.2320
-8.94%
 
RFM.F Sensorion SA
0.5800
-0.68%
 
AYJ.DE Valneva SE
3.6960
-6.67%
 
ALTME.PA TME Pharma N.V.
0.0753
+1.07%
 
BX2.F BioXcel Therapeutics, Inc.
0.0000
-30.22%
 
J90.F NurExone Biologic Inc.
0.4440
+11.56%